Physician profile
Jaynah Mistry
NPI 1568915015
$8,361.40
in general payments reported to CMS, 2019-2025
64 companies · $2,221 in 2025
The $2,221 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $1,806 · 2023: $2,228 · 2024: $1,880 · 2025: $2,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,329.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $865.31 | 2022-2025 | |
| Janssen Biotech, INC. | $738.67 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $700.07 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $372.01 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Pharmaceuticals, INC | $346.74 | 2021-2023 | Xarelto |
| Daiichi Sankyo INC. | $309.13 | 2022-2025 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $248.58 | 2022-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Abbvie INC. | $231.91 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $215.61 | 2022-2025 | |
| Lilly USA, LLC | $208.35 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $203.50 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $201.11 | 2022-2025 | Tecentriq, Lunsumio, Polivy |
| Astrazeneca Pharmaceuticals LP | $193.83 | 2023-2025 | Lynparza, Calquence, Imfinzi |
| Seagen INC. | $180.60 | 2022-2023 | Tivdak, Tukysa |
| Eisai INC. | $180.25 | 2022-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $180.19 | 2023-2025 | Besremi |
| Ipsen Biopharmaceuticals, INC | $176.96 | 2022-2025 | Onivyde, Tazverik, Somatuline Depot |
| Genzyme Corporation | $160.35 | 2022-2025 | |
| Tersera Therapeutics LLC | $149.50 | 2022-2025 | Zoladex, Xermelo, Quzyttir |
| Taiho Oncology, INC. | $133.29 | 2022-2025 | |
| Amgen INC. | $132.61 | 2022-2023 | Xgeva, Vectibix, Nplate |
| Novo Nordisk INC | $125.00 | 2022 | |
| Pfizer INC. | $123.53 | 2021-2025 | |
| Adc Therapeutics America, INC. | $122.82 | 2022-2025 | |
| Exelixis INC. | $117.01 | 2022-2025 | Cabometyx |
| Kyowa Kirin, INC. | $109.90 | 2023-2025 | Poteligeo |
| Puma Biotechnology, INC. | $104.22 | 2022-2025 | |
| Glaxosmithkline, LLC. | $103.84 | 2024-2025 | Jemperli, Zejula |
| Mirati Therapeutics, INC. | $101.30 | 2023-2024 | Krazati |
| Davol INC. | $92.57 | 2023 | Arista Ah Flexitip |
| Karyopharm Therapeutics INC. | $82.13 | 2022-2024 | Xpovio |
| Beone Medicines USA, INC. | $74.71 | 2025 | Brukinsa |
| Genmab U.S., INC. | $68.77 | 2025 | Epkinly |
| G1 Therapeutics, INC. | $66.75 | 2022-2023 | Cosela |
| Sobi, INC | $66.41 | 2025 | |
| Array Biopharma INC | $62.72 | 2023-2025 | Lorbrena, Mektovi, Braftovi |
| Alexion Pharmaceuticals, INC. | $61.73 | 2024 | Ultomiris |
| Blueprint Medicines Corporation | $51.30 | 2022-2025 | Ayvakit |
| Pharmacosmos Therapeutics INC. | $49.31 | 2022-2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $45.21 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Morphosys, US INC. | $44.61 | 2022-2023 | Monjuvi |
| Astellas Pharma US INC | $42.08 | 2023-2025 | Padcev, Xospata |
| Deciphera Pharmaceuticals INC. | $41.74 | 2022-2025 | Qinlock, Tgct |
| Alnylam Pharmaceuticals INC. | $40.65 | 2023-2024 | Givlaari |
| Heron Therapeutics, INC. | $31.92 | 2023 | Sustol |
| Mylan Specialty L.P. | $30.56 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.44 | 2022 | |
| Emd Serono, INC. | $26.38 | 2025 | |
| Fennec Pharmaceuticals, INC. | $24.92 | 2025 | Fyarro |
| Tolmar Pharmaceuticals, INC. | $24.79 | 2022 | |
| Fresenius Kabi USA, LLC | $24.43 | 2025 | Stimufend |
| Invivyd INC | $23.64 | 2024 | Pemgarda |
| Janssen Scientific Affairs, LLC | $23.07 | 2023 | Darzalex, Tecvayli |
| Agios Pharmaceuticals, INC. | $22.99 | 2024 | Pyrukynd |
| Syndax Pharmaceuticals, INC. | $22.84 | 2025 | |
| Spectrum Pharmaceuticals INC. | $21.96 | 2024 | Rolvedon |
| Beigene USA, INC. | $18.61 | 2022 | |
| Smith+Nephew, INC. | $18.12 | 2021 | |
| Adaptive Biotechnologies Corporation | $17.11 | 2025 | Clonoseq |
| Recordati_rare_diseases_inc. | $15.74 | 2023 | Sylvant |
| Sanofi-Aventis U.S. LLC | $15.51 | 2022 | |
| Servier Pharmaceuticals LLC | $15.03 | 2022 | |
| Tactile Systems Technology INC | $14.96 | 2025 | Nimbl, Flexitouch Plus |
| Celgene Corporation | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaynah Mistry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.